Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,201 to 2,220 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Palliative Care Team (PCTeam) vs Standard Care: Number of Nursing Home Residents in Moderate-to-severe Pain | 235 of 1,844 218 of 1,851 | 1.0 points -1.2 to 3.1 | 3,695 | NCT01990742 Improving Palliative Care Through Teamwork |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s) | 1,489 of 2,769 503 of 923 | -0.7 points -4.4 to 3.0 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs) | 1,010 of 2,769 334 of 923 | 0.3 points -3.3 to 3.8 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Serious Adverse Events (SAEs) | 47 of 2,769 18 of 923 | -0.3 points -1.4 to 0.6 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Physicians (MD) Office Visits | 668 of 2,769 205 of 923 | 1.9 points -1.3 to 5.0 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting New Onset of Chronic Illness(es) (NOCDs) | 85 of 2,769 33 of 923 | -0.5 points -2.0 to 0.7 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Rash | 265 of 2,769 94 of 923 | -0.6 points -3.0 to 1.5 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Adverse Events Resulting in Emergency Room (ER) Visits | 137 of 2,769 54 of 923 | -0.9 points -2.8 to 0.7 | 3,692 | NCT00289783 Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine |
| PCI at Hospitals Without On-Site Cardiac Surgery vs PCI at Hospital With On-Site Cardiac Surgery: Emergency or Urgent Revascularization | 7 of 2,774 2 of 917 | 0.0 points -0.6 to 0.3 | 3,691 | NCT01116882 Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings |
| Donning Non-Sterile Gloves Without Hand Hygiene vs Hand Hygiene Before Donning Non-Sterile Gloves: Proportion of Healthcare Worker Who Perform Hand Hygiene on Exit From Any Room | 1,525 of 1,785 1,587 of 1,897 | 1.8 points -0.6 to 4.1 | 3,682 | NCT03119389 Direct Gloving Strategy: A Cluster-randomized Trial |
| Influenza Vaccine vs Placebo: deaths from any cause | 1 of 1,829 0 of 1,841 | 0.1 points -0.2 to 0.3 | 3,670 | NCT00566345 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) |
| Influenza Vaccine vs Placebo: serious adverse events | 3 of 1,829 0 of 1,841 | 0.2 points -0.1 to 0.5 | 3,670 | NCT00566345 Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII) |
| Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo: Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled) | 152 of 1,834 192 of 1,834 | -2.2 points -4.1 to -0.3 | 3,668 | NCT01858532 Study Of Diabetic Nephropathy With Atrasentan |
| Facility-based Screening vs Contact Screening: Treatment Initiation Ratio in Facility Versus Contact Investigation Clinics | 1,929 of 1,929 1,726 of 1,726 | 0.0 points -0.2 to 0.2 | 3,655 | NCT02808507 Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa |
| XIENCE V® vs TAXUS™ EXPRESS 2™: serious adverse events | 913 of 2,436 468 of 1,214 | -1.1 points -4.4 to 2.3 | 3,650 | NCT00307047 SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System |
| Canadian Td Vaccine Group vs United States Td Vaccine Group: serious adverse events | 58 of 2,950 44 of 700 | -4.3 points -6.4 to -2.7 | 3,650 | NCT00601835 Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td |
| Arm I vs Arm II: Breast Cancer-specific Mortality | 155 of 1,824 160 of 1,825 | -0.3 points -2.1 to 1.6 | 3,649 | NCT01101438 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer |
| Metformin vs Placebo: deaths from any cause | 201 of 1,824 198 of 1,825 | 0.2 points -1.9 to 2.2 | 3,649 | NCT01101438 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer |
| HEART Care vs Usual Care: MACE (Major Adverse Cardiac Events) | 345 of 1,821 405 of 1,827 | -3.2 points -5.8 to -0.6 | 3,648 | NCT01756846 Impact on Management of the HEART Risk Score in Chest Pain Patients |
| HEART Care vs Usual Care: deaths from any cause | 5 of 1,821 9 of 1,827 | -0.2 points -0.7 to 0.2 | 3,648 | NCT01756846 Impact on Management of the HEART Risk Score in Chest Pain Patients |
Code
curl "https://conductscience.org/api/comparisons/v1?page=111"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=111
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01990742-2bcf7e19",
"title": "Palliative Care Team (PCTeam) vs Standard Care: Number of Nursing Home Residents in Moderate-to-severe Pain",
"summary": "235 of 1844 against 218 of 1851; risk difference 1.0 points, 95% interval -1.2 to 3.1; NCT01990742, Improving Palliative Care Through Teamwork",
"record": "/library/comparisons/NCT01990742-2bcf7e19",
"nct_id": "NCT01990742",
"kind": "outcome",
"participants": 3695,
"risk_difference": {
"value": 0.009666170950567862,
"lower": -0.011511383235578907,
"upper": 0.03085901423225643
},
"group_1": "235 of 1,844",
"group_2": "218 of 1,851",
"difference": "1.0 points",
"interval": "-1.2 to 3.1",
"trial_title": "Improving Palliative Care Through Teamwork"
},
{
"id": "NCT00289783-0806ded5",
"title": "Menhibrix Group vs ActHIB Group: Number of Subjects Reporting Increased Circumferential Swelling at the Injection Limb(s)",
"summary": "1489 of 2769 against 503 of 923; risk difference -0.7 points, 95% interval -4.4 to 3.0; NCT00289783, Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine",
"record": "/library/comparisons/NCT00289783-0806ded5",
"nct_id": "NCT00289783",
"kind": "outcome",
"participants": 3692,
"risk_difference": {
"value": -0.007222824124232585,
"lower": -0.044131233620242474,
"upper": 0.029955764467501693
},
"group_1": "1,489 of 2,769",
"group_2": "503 of 923",
"difference": "-0.7 points",
"interval": "-4.4 to 3.0",
"trial_title": "Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=112",
"request_id": "wjZV1AHe2YtO-Y3_"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant